ArticleFrontiers in medicine2021
Response to Immune Checkpoint Inhibitor Treatment in Advanced Cervical Cancer and Biomarker Study.
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for esophageal cancer treatment: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Circulating and tumor-infiltrating immune cell profiles in cervical cancer checkpoint blockade: multi-omics biomarkers of response and resistance.Frontiers in immunology · 2026Review
- Real-world multicenter study of immune checkpoint inhibitors in advanced cervical cancer across HPV-associated and HPV-independent subtypes.International journal of clinical oncology · 2026Article
- Research hotspots and trends in the field of immune checkpoint inhibitors (ICIs) for cervical cancer: A bibliometric study from 2014 to 2024.Human vaccines & immunotherapeutics · 2025Article
- Interplay Between Immune Microenvironment CD8Medicina (Kaunas, Lithuania) · 2025Article
- Identification and validation of inflammatory subtypes in intrahepatic cholangiocellular carcinoma.Journal of translational medicine · 2024Article
- Article
- Systematic Review on the Effectiveness and Outcomes of Nivolumab Treatment Schemes in Advanced and Metastatic Cervical Cancer.Diseases (Basel, Switzerland) · 2024Review
- Investigating tumor-host response dynamics in preclinical immunotherapy experiments using a stepwise mathematical modeling strategy.Mathematical biosciences · 2023Article
- Serum cell division cycle 42 reflects the treatment response and survival in patients with advanced cervical cancer who receive immune checkpoint inhibitor treatment.Oncology letters · 2023Article
- Immune checkpoint inhibitor therapy in advanced cervical cancer: Deepened response with prolonged treatment and repeat response to re-initiation of therapy.Gynecologic oncology reports · 2023Article
- Immune checkpoint inhibition: a future guided by radiology.The British journal of radiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.